BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Qi J, Cao H, Liu C. Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice. Virol Sin 2021;36:122-32. [PMID: 32757147 DOI: 10.1007/s12250-020-00261-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 K D, Venugopal S. Therapeutic potential of selenium nanoparticles. Front Nanotechnol 2022;4. [DOI: 10.3389/fnano.2022.1042338] [Reference Citation Analysis]
2 Luan N, Cao H, Wang Y, Cunbao Liu KL. LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with ShingrixTM in VZV-primed mice. Virol Sin 2022:S1995-820X(22)00108-0. [PMID: 35671982 DOI: 10.1016/j.virs.2022.06.002] [Reference Citation Analysis]
3 Liu J, Lin J, Cai L, Sun J, Ding X, Wang C, Wu Y, Gao X, Su W, Jiang C. Immunogenicity of Varicella Zoster Virus DNA Vaccines Encoding Glycoprotein E and Immediate Early Protein 63 in Mice. Viruses 2022;14:1214. [DOI: 10.3390/v14061214] [Reference Citation Analysis]
4 Cao H, Wang Y, Luan N, Lin K, Liu C. Effects of Varicella-Zoster Virus Glycoprotein E Carboxyl-Terminal Mutation on mRNA Vaccine Efficacy. Vaccines (Basel) 2021;9:1440. [PMID: 34960186 DOI: 10.3390/vaccines9121440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cao H, Yang S, Wang Y, Luan N, Yin X, Lin K, Liu C. An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines. Vaccines (Basel) 2021;9:1261. [PMID: 34835192 DOI: 10.3390/vaccines9111261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Cao H, Wang Y, Luan N, Liu C. Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice. Vaccines (Basel) 2021;9:310. [PMID: 33805880 DOI: 10.3390/vaccines9040310] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]